Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 2
1979 1
1980 2
1981 1
1982 3
1983 6
1984 1
1985 3
1986 3
1987 4
1988 5
1989 5
1990 5
1991 11
1992 6
1993 6
1994 12
1995 7
1996 8
1997 13
1998 14
1999 6
2000 17
2001 11
2002 14
2003 14
2004 13
2005 17
2006 18
2007 25
2008 17
2009 26
2010 26
2011 23
2012 34
2013 36
2014 41
2015 34
2016 42
2017 37
2018 40
2019 42
2020 57
2021 48
2022 24
2023 23
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

713 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Susceptibility to myeloid leukemia"
Page 1
Advances in acute myeloid leukemia.
Newell LF, Cook RJ. Newell LF, et al. BMJ. 2021 Oct 6;375:n2026. doi: 10.1136/bmj.n2026. BMJ. 2021. PMID: 34615640 Review.
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and diseas …
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The …
Treatment of Relapsed Acute Myeloid Leukemia.
Thol F, Ganser A. Thol F, et al. Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5. Curr Treat Options Oncol. 2020. PMID: 32601974 Free PMC article. Review.
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40-50% of younger and the great majority of elderly patients. ...At the time of relapse, we again perform a mutational screening and cytogenetic analysis in all AML patients a …
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40-50% of younger and the great maj …
Leukemic stem cells and therapy resistance in acute myeloid leukemia.
Stelmach P, Trumpp A. Stelmach P, et al. Haematologica. 2023 Feb 1;108(2):353-366. doi: 10.3324/haematol.2022.280800. Haematologica. 2023. PMID: 36722405 Free PMC article. Review.
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or relapse after achieving remission. ...This review discusses LSC biology and associated resistance mechanisms, potential therapeutic LSC vulnerabilities and current c …
A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or relapse after achieving remi …
Chronic myeloid leukemia stem cells.
Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP. Houshmand M, et al. Leukemia. 2019 Jul;33(7):1543-1556. doi: 10.1038/s41375-019-0490-0. Epub 2019 May 24. Leukemia. 2019. PMID: 31127148 Free PMC article. Review.
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML leukemia stem cell (LSC). In humans a CML LSC is operationally-defined by 1 in v …
Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological potential, intrinsic or acquired, to cause …
Updates on targeted therapies for acute myeloid leukaemia.
Kayser S, Levis MJ. Kayser S, et al. Br J Haematol. 2022 Jan;196(2):316-328. doi: 10.1111/bjh.17746. Epub 2021 Aug 4. Br J Haematol. 2022. PMID: 34350585 Review.
In the past few years research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable advances in our understanding of the disease. ...Our increased understanding of the pathogenesis of AML facilitated by next-generatio …
In the past few years research in the underlying pathogenic mechanisms of acute myeloid leukaemia (AML) has led to remarkable …
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Ullmann AJ, et al. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12. Clin Microbiol Infect. 2018. PMID: 29544767 Free article.
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. ...Pathogen identification to sp …
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the Europe …
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. Issa GC, et al. Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15. Nature. 2023. PMID: 36922593 Free PMC article. Clinical Trial.
KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, forming the most common genetic alteration in acute myeloid leukaemia(7,8). Here, we describe the results of the first-in-human phas …
KMT2A rearrangements occur in up to 10% of acute leukaemias and have an adverse prognosis, whereas NPM1 mutations occur in up to 30%, formin …
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group. Metzeler KH, et al. Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10. Blood. 2016. PMID: 27288520 Free article. Clinical Trial.
The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined. ...Furthermore, we provide detailed information on associations between gene mutations, clinical patient ch …
The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia …
Myelodysplastic Syndromes.
Cazzola M. Cazzola M. N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794. N Engl J Med. 2020. PMID: 32997910 Review. No abstract available.
C/EBPalpha Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia.
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I, Heiblig M, Boet E, Sahal A, Saland E, Santos JC, Armengol M, Fernández-Serrano M, Farge T, Cognet G, Simonetta F, Pignon C, Graffeuil A, Mazzotti C, Avet-Loiseau H, Delos O, Bertrand-Michel J, Chedru A, Dembitz V, Gallipoli P, Anstee NS, Loo S, Wei AH, Carroll M, Goubard A, Castellano R, Collette Y, Vergez F, Mansat-De Mas V, Bertoli S, Tavitian S, Picard M, Récher C, Bourges-Abella N, Granat F, Kosmider O, Sujobert P, Colsch B, Joffre C, Stuani L, Swinnen JV, Guillou H, Roué G, Hakim N, Dejean AS, Tsantoulis P, Larrue C, Bouscary D, Tamburini J, Sarry JE. Sabatier M, et al. Cancer Discov. 2023 Jul 7;13(7):1720-1747. doi: 10.1158/2159-8290.CD-22-0411. Cancer Discov. 2023. PMID: 37012202
Here, multiomics analyses uncovered a coordinated activation of C/EBPalpha and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabolism in vivo and in patients with FLT3-mutant acute myeloid leukemia (AML). Mechanistically, C/EBPalpha regulated the fatty aci …
Here, multiomics analyses uncovered a coordinated activation of C/EBPalpha and Fms-like tyrosine kinase 3 (FLT3) that increased lipid anabol …
713 results